A growing movement, particularly in the US, legally allows patients with terminal diseases to try unapproved therapies. This framework gives patients who have exhausted all other options the right to take a knowing risk on a potentially life-saving treatment.

Drug developers often operate under a hyper-conservative perception of FDA requirements, avoiding novel approaches even when regulators might encourage them. This anticipatory compliance, driven by risk aversion, becomes a greater constraint than the regulations themselves, slowing down innovation and increasing costs.

The push for AI regulation risks repeating mistakes made in pharmaceuticals, where a singular focus on safety, without balancing it against potential benefits, led to regulatory capture and slowed progress. This could cripple AI's potential for societal good in healthcare, energy, and more.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

Regulating technology based on anticipating *potential* future harms, rather than known ones, is a dangerous path. This 'precautionary principle,' common in Europe, stifles breakthrough innovation. If applied historically, it would have blocked transformative technologies like the automobile or even nuclear power, which has a better safety record than oil.

The FDA's traditional focus on risk avoidance overlooks the inherent risk of delay. Unnecessary bureaucratic steps, like months of animal trials, prevent dying patients from accessing potentially life-saving treatments. The cost of inaction is measured in lives lost.

The UK's MHRA is pursuing a philosophical shift in its regulatory role. Its CEO argues the agency's purpose is not to hold back potential therapies but to make them available, provided the patient and clinician understand and accept the benefit-risk parameters. This redefines the regulator as an enabler of patient-centric innovation.

The 'precautionary principle,' or regulating before harm occurs, is a bureaucratic trap. It provides justification for regulators to act on speculation, which constrains the solution space and stifles the experimentation needed for a technology to reach its full potential.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.